A phase II trial for Mefatinib (MET-306) 60mg or 80mg in the treatment of 1st Line EGFR Mutation in Patients with advanced non-small cell lung cancer
Latest Information Update: 08 Mar 2021
At a glance
- Drugs Mefatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Hangzhou Zhongmei Huadong Pharmaceutical; Huadong Medicine
Most Recent Events
- 08 Mar 2021 New trial record
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer